Biomarkers in Samples From Patients With Down Syndrome and Acute Megakaryoblastic Leukemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01139307|
Recruitment Status : Completed
First Posted : June 8, 2010
Last Update Posted : February 23, 2016
RATIONALE: Studying samples of blood or tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study is studying biomarkers in samples from patients with Down syndrome and acute megakaryoblastic leukemia.
|Condition or disease||Intervention/treatment|
|Leukemia||Other: cell culture procedure Other: laboratory biomarker analysis|
- Determine whether megakaryocyte differentiation agents comprising a Rho kinase inhibitor and a JAK3 inhibitor can lead to proliferation arrest, polyploidization, and terminal differentiation of blasts in specimens from patients with Down syndrome and acute megakaryoblastic leukemia.
OUTLINE: Cryopreserved specimens are cultured and treated in vivo (in mice) and in vitro with megakaryocytic differentiation agents comprising a Rho kinase inhibitor and a JAK3 inhibitor.
|Study Type :||Observational|
|Estimated Enrollment :||10 participants|
|Official Title:||Development of Novel Therapeutics for AMKL|
|Study Start Date :||July 2009|
|Actual Primary Completion Date :||August 2012|
- Proliferation arrest
- Terminal differentiation
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01139307
|Principal Investigator:||John Crispino, PhD||Robert H. Lurie Cancer Center|